Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company's business specializes in the development, production and sale of medications that serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, Inc. (Visionology), a direct-to-consumer eye care subsidiary focused on chronic eye disease. In addition, the Company holds non-controlling equity positions in Surface Ophthalmics, Inc. (Surface) and Melt Pharmaceuticals, Inc. (Melt). It also owns royalty rights in various drug candidates being developed by Surface and Melt.
During the most recent quarter, 41K shares were bought in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.